Nothing Special   »   [go: up one dir, main page]

MX346643B - Virus de la enfermedad de newcastle y su uso como vacuna. - Google Patents

Virus de la enfermedad de newcastle y su uso como vacuna.

Info

Publication number
MX346643B
MX346643B MX2010012602A MX2010012602A MX346643B MX 346643 B MX346643 B MX 346643B MX 2010012602 A MX2010012602 A MX 2010012602A MX 2010012602 A MX2010012602 A MX 2010012602A MX 346643 B MX346643 B MX 346643B
Authority
MX
Mexico
Prior art keywords
newcastle disease
disease virus
vaccine
viruses
newcastle
Prior art date
Application number
MX2010012602A
Other languages
English (en)
Other versions
MX2010012602A (es
Inventor
Lucio Decanini Eduardo
Andrés Morales Garzón José
Eduardo Absalón Constantino Ángel
Verónica Cortes Espinoza Diana
Original Assignee
Investig Aplicada S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Investig Aplicada S A De C V filed Critical Investig Aplicada S A De C V
Priority to MX2010012602A priority Critical patent/MX346643B/es
Priority to US13/988,046 priority patent/US9370563B2/en
Priority to PCT/MX2011/000141 priority patent/WO2012067483A2/es
Priority to ARP110104326A priority patent/AR083935A1/es
Publication of MX2010012602A publication Critical patent/MX2010012602A/es
Publication of MX346643B publication Critical patent/MX346643B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18161—Methods of inactivation or attenuation
    • C12N2760/18163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a nuevos virus de Newcastle de cualquier genotipo y fragmentos novedosos del genoma del virus de la enfermedad de Newcastle que codifican para las proteínas F y HN, construidos mediante genética reversa y recombinación, de alta antigenicidad para la elaboración de vacunas para la prevención de la enfermedad de Newcastle mediante la reducción de la excreción viral o para su utilización como vectores con otros virus en forma liofilizada o emulsionada en aceite. Asimismo se puede usar como vector en combinación con otros agentes patogénicos.
MX2010012602A 2010-11-18 2010-11-18 Virus de la enfermedad de newcastle y su uso como vacuna. MX346643B (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2010012602A MX346643B (es) 2010-11-18 2010-11-18 Virus de la enfermedad de newcastle y su uso como vacuna.
US13/988,046 US9370563B2 (en) 2010-11-18 2011-11-18 Newcastle disease virus and the use thereof as a vaccine
PCT/MX2011/000141 WO2012067483A2 (es) 2010-11-18 2011-11-18 Virus de la enfermedad de newcastle y su uso como vacuna
ARP110104326A AR083935A1 (es) 2010-11-18 2011-11-21 Virus de la enfermedad de newcastle y su uso como vacuna y vector

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010012602A MX346643B (es) 2010-11-18 2010-11-18 Virus de la enfermedad de newcastle y su uso como vacuna.

Publications (2)

Publication Number Publication Date
MX2010012602A MX2010012602A (es) 2012-05-18
MX346643B true MX346643B (es) 2016-11-11

Family

ID=46084559

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012602A MX346643B (es) 2010-11-18 2010-11-18 Virus de la enfermedad de newcastle y su uso como vacuna.

Country Status (4)

Country Link
US (1) US9370563B2 (es)
AR (1) AR083935A1 (es)
MX (1) MX346643B (es)
WO (1) WO2012067483A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3596204A1 (en) * 2017-03-14 2020-01-22 Centre de Coopération Internationale en Recherche Agronomique pour le Développement - C.I.R.A.D. Improved reverse genetics for single strand negative rna viruses
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN110684746A (zh) * 2019-09-26 2020-01-14 北京市动物疫病预防控制中心 一种冻干型新城疫病毒核酸标准物质的制备方法及其检测方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신

Also Published As

Publication number Publication date
US20130315956A1 (en) 2013-11-28
US9370563B2 (en) 2016-06-21
WO2012067483A2 (es) 2012-05-24
MX2010012602A (es) 2012-05-18
WO2012067483A3 (es) 2012-07-19
AR083935A1 (es) 2013-04-10

Similar Documents

Publication Publication Date Title
PH12017500727A1 (en) Modified virus-like particles of cmv
MX2013004159A (es) Proteina vp6 de la capside de norovirus y de rotavirus para el uso como vacuna combinada.
CL2013002712A1 (es) Composicion inmunogénica para modular sistema inmune que comprende agentes con patrones asociados a bacterias, virus, hongos y levaduras, protozoos, helmintos y/o priones; uso para tratar enfermedades autoinmunes o infecciosas.
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2016004063A (es) Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
MX352604B (es) Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah.
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
PL2658570T3 (pl) Sposoby i kompozycje szczepionki przeciwko wirusowi wirusowej biegunki bydła typu 1b
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2008115314A3 (en) Flavivirus vaccine vector against influenza virus
WO2012024283A3 (en) Universal influenza a vaccines
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
MX2010012602A (es) Virus de la enfermedad de newcastle y su uso como vacuna.
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
CO6700818A2 (es) Vectores de parapoxvirus
CO6670515A2 (es) Vectores de parapoxvirus
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
MX350718B (es) Vacuna de rinitis equina.
MX360831B (es) Virus de influenza c y vacuna.
HK1255682A1 (zh) 改性馬立克氏病病毒及從其製備的疫苗
MX2014004537A (es) Vacunas para el virus del papiloma humano y metodos para su uso.
WO2011130652A3 (en) Compositions and methods for vaccinating humans and animals against enveloped viruses
BRPI0819031A2 (pt) processo para preparar cepas virais atenuadas, vírus atenuado, uso de uma cepa viral atenuada e vacina baseada em vírus atenuado vivos.

Legal Events

Date Code Title Description
FG Grant or registration